Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China

OBJECTIVE: To evaluate the economics of sugemalimab plus chemotherapy in the first-line treatment of metastatic non-small cell lung cancer, and to provide a reference for the formulation of relevant medical insurance policies and rational drug use. METHODS: From the perspective of the Chinese health...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hao, Liao, Li, Xu, Yuan, Long, Yunchun, Wang, Ye, Zhou, Yujie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792693/
https://www.ncbi.nlm.nih.gov/pubmed/36582798
http://dx.doi.org/10.3389/fonc.2022.1081750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792693/
https://www.ncbi.nlm.nih.gov/pubmed/36582798
http://dx.doi.org/10.3389/fonc.2022.1081750

Ejemplares similares